micro skit

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/12

encourage image

There's no tags or description

Looks like no tags are added yet.

13 Terms

1
New cards

TRAINER: Professor! Tomorrow we challenge the Legendary Pokémon HIV-1. My Partner has been training all week. (shakes the plushie) Do you have any advice for us?

PROFESSOR: Slow down. HIV-1 is no ordinary boss. It infects immune cells, and once it embeds its genes into your DNA, it never leaves. No one has ever knocked it out for good.

2
New cards

TRAINER: Never?

PROFESSOR: Never. That's why the smartest strategy is ✨prevention✨. In order to prevent HIV, you can use protection and get tested regularly. You can also undergo pre-exposure prophylaxis, or PrEP, which means taking medication before you are ever exposed.

3
New cards

TRAINER: A medicine before the battle? Like a held item? (next slide)

PROFESSOR: Exactly. (Professor holds up the item.) This is the item Lenacapavir.

4
New cards

TRAINER: Lena-what?

PROFESSOR: Len-a-CAP-a-veer. It’s an antiviral, where it acts as a capsid inhibitor. It is the first one ever to be approved, and protects the holder from HIV-1 for six months.

5
New cards

TRAINER: Six months from one item? I heard the other PrEP items are pills you take every single day.

PROFESSOR: That's what makes this one special. A healthcare provider gives it as injections under the skin once every six months, forming a small depot that slowly releases the drug over time.

6
New cards

TRAINER: Where does it come from? (next slide)

PROFESSOR: It is a fully synthetic small molecule, designed by chemists at Gilead Sciences in California. (next slide)

7
New cards

TRAINER: And when did it reach the shops?

PROFESSOR: It was first marketed in 2022 under the brand name Sunlenca. It was approved in Europe in August, and then by the FDA in December that same year. Back then, it was only for treatment. Three years later, in June 2025, the FDA approved a second brand name, Yeztugo, for HIV prevention.

8
New cards

TRAINER: Wait, what does it treat? (next slide)

PROFESSOR: Lenacapavir can be used for either treatment or prevention. For treatment, it’s used for adults with multidrug-resistant HIV-1 in combination with other antiretrovirals when other medications are failing. For prevention, it’s used for adults and adolescents at risk of getting HIV through sexual transmission.

9
New cards

TRAINER: Okay, using Lenacapavir as a prevention of HIV-1 sounds like a perfect strategy for the battle. We'll take it!

PROFESSOR: Not so fast. First, an HIV test. This item is only for someone who is HIV-negative. (Scans the Partner with a gadget and makes a beep) (next slide) Negative. Great! Here’s the item.

10
New cards

HIV-1: It's stuck! I can't get my genome into the nucleus! 

TRAINER: The Lenacapavir item worked! With nuclear import blocked, the virus can't integrate into the host's DNA.

HIV-1: Then I'll build new copies of myself!


PROFESSOR: Not so fast! Lenacapavir works late in the HIV life cycle too. It interferes with capsid production, viral assembly, and release. The capsid monomers turn into abnormal forms with reduced infectivity.

11
New cards

HIV-1: My capsid! And my copies can't properly infect new cells!

TRAINER: That’s right! Lenacapavir disrupts multiple stages of HIV replication with just one molecular target, which distinguishes it from older medicines that target the HIV enzyme.


PROFESSOR: But beware of the biggest risk of using Lenacapavir: resistance. It usually happens when doses are missed, but also occurs when PrEP is given to someone with undiagnosed HIV or when the drug is used without strong partner drugs. The good news is that nothing else targets the capsid, so there is no cross-resistance with other drug classes.

12
New cards

TRAINER: Partner? You don't look so good. 


PROFESSOR: Quick! You should head to the Pokémon Center! (next slide)


13
New cards

TRAINER: (opens an empty wallet) I’m broke as hell, Nurse Joy. (next slide)

NURSE JOY: I know. These companies charge an absurd amount of money, but interestingly, researchers estimate a generic version could be made for 25 to 46 dollars per person per year. (next slide)

The Professor walks in.



PROFESSOR: Great job with the battle, Trainer Sarah! How is your partner? (next slide)